Literature DB >> 27696765

Lung function, respiratory symptoms and venous thromboembolism risk: the Atherosclerosis Risk in Communities Study.

Y Kubota1,2, S J London3, M Cushman4, A M Chamberlain5, W D Rosamond6, S R Heckbert7, N Zakai4, A R Folsom1.   

Abstract

Essentials The association of lung function with venous thromboembolism (VTE) is unclear. Chronic obstructive pulmonary disease (COPD) patterns were associated with a higher risk of VTE. Symptoms were also associated with a higher risk of VTE, but a restrictive pattern was not. COPD may increase the risk of VTE and respiratory symptoms may be a novel risk marker for VTE.
SUMMARY: Background The evidence for the association between chronic obstructive pulmonary disease (COPD) and venous thromboembolism (VTE) is limited. There is no study investigating the association between restrictive lung disease (RLD) and respiratory symptoms with VTE. Objectives To investigate prospectively the association of lung function and respiratory symptoms with VTE. Patients/Methods In 1987-1989, we assessed lung function by using spirometry, and obtained information on respiratory symptoms (cough, phlegm, and dyspnea) in 14 654 participants aged 45-64 years, without a history of VTE or anticoagulant use, and followed them through 2011. Participants were classified into four mutually exclusive groups: 'COPD' (forced expiratory volume in 1 s [FEV1 ]/forced vital capacity [FVC] below the lower limit of normal [LLN]), 'RLD' (FEV1 /FVC ≥ LLN and FVC < LLN), 'respiratory symptoms with normal spirometic results' (without RLD or COPD), and 'normal' (without respiratory symptoms, RLD, or COPD). Results We documented 639 VTEs (238 unprovoked and 401 provoked VTEs). After adjustment for VTE risk factors, VTE risk was increased for individuals with either respiratory symptoms with normal spirometric results (hazard ratio [HR] 1.40, 95% confidence interval [CI] 1.12-1.73) or COPD (HR 1.33, 95% CI 1.07-1.67) but not for those with RLD (HR 1.15, 95% CI 0.82-1.60). These elevated risks of VTE were derived from both unprovoked and provoked VTE. Moreover, FEV1 and FEV1 /FVC showed dose-response relationships with VTE. COPD was more strongly associated with pulmonary embolism than with deep vein thrombosis. Conclusions Obstructive spirometric patterns were associated with an increased risk of VTE, suggesting that COPD may increase the risk of VTE. Respiratory symptoms may represent a novel risk marker for VTE.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  chronic obstructive pulmonary disease; lung function; respiratory symptoms; restrictive lung disease; venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27696765      PMCID: PMC5378065          DOI: 10.1111/jth.13525

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  34 in total

Review 1.  Systematic review of the association between lung function and Type 2 diabetes mellitus.

Authors:  O L Klein; J A Krishnan; S Glick; L J Smith
Journal:  Diabet Med       Date:  2010-09       Impact factor: 4.359

2.  Introducing the COPD Foundation Guide for Diagnosis and Management of COPD, recommendations of the COPD Foundation.

Authors:  Stephen Rennard; Byron Thomashow; James Crapo; Barbara Yawn; Andrew McIvor; Scott Cerreta; John Walsh; David Mannino
Journal:  COPD       Date:  2013-06       Impact factor: 2.409

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 4.  Adverse effects of glucocorticoids: coagulopathy.

Authors:  Maria Caroline Alves Coelho; Camila Vicente Santos; Leonardo Vieira Neto; Mônica R Gadelha
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

5.  COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program.

Authors:  Stephen Sidney; Michael Sorel; Charles P Quesenberry; Cynthia DeLuise; Stephan Lanes; Mark D Eisner
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

6.  Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction.

Authors:  M P Swanney; G Ruppel; P L Enright; O F Pedersen; R O Crapo; M R Miller; R L Jensen; E Falaschetti; J P Schouten; J L Hankinson; J Stocks; P H Quanjer
Journal:  Thorax       Date:  2008-09-11       Impact factor: 9.139

7.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.

Authors:  Mette Thomsen; Truls Sylvan Ingebrigtsen; Jacob Louis Marott; Morten Dahl; Peter Lange; Jørgen Vestbo; Børge G Nordestgaard
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

8.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

9.  COPD and risk of venous thromboembolism and mortality in a general population.

Authors:  Trond Børvik; Sigrid K Brækkan; Kristin Enga; Henrik Schirmer; Ellen E Brodin; Hasse Melbye; John-Bjarne Hansen
Journal:  Eur Respir J       Date:  2015-11-19       Impact factor: 16.671

Review 10.  Prevalence and prevention of venous thromboembolism in patients with acute exacerbations of COPD.

Authors:  Marco Ambrosetti; Walter Ageno; Antonio Spanevello; Mario Salerno; Roberto F E Pedretti
Journal:  Thromb Res       Date:  2003       Impact factor: 3.944

View more
  14 in total

1.  Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Christie M Ballantyne; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-11-26       Impact factor: 5.162

2.  Impaired Lung Function, Lung Disease, and Risk of Incident Dementia.

Authors:  Pamela L Lutsey; Nemin Chen; Maria C Mirabelli; Kamakshi Lakshminarayan; David S Knopman; Keith A Vossel; Rebecca F Gottesman; Thomas H Mosley; Alvaro Alonso
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

3.  Diabetes-related factors and abdominal aortic aneurysm events: the Atherosclerotic Risk in Communities Study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; James S Pankow; Lynne E Wagenknecht; Weihong Tang
Journal:  Ann Epidemiol       Date:  2017-12-16       Impact factor: 3.797

4.  Heart rate variability and lifetime risk of cardiovascular disease: the Atherosclerosis Risk in Communities Study.

Authors:  Yasuhiko Kubota; Lin Y Chen; Eric A Whitsel; Aaron R Folsom
Journal:  Ann Epidemiol       Date:  2017-10-03       Impact factor: 3.797

5.  TV viewing and incident venous thromboembolism: the Atherosclerotic Risk in Communities Study.

Authors:  Yasuhiko Kubota; Mary Cushman; Neil Zakai; Wayne D Rosamond; Aaron R Folsom
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

6.  Physical Activity and Lifetime Risk of Cardiovascular Disease and Cancer.

Authors:  Yasuhiko Kubota; Kelly R Evenson; Richard F Maclehose; Nicholas S Roetker; Corinne E Joshu; Aaron R Folsom
Journal:  Med Sci Sports Exerc       Date:  2017-08       Impact factor: 5.411

7.  Prospective study of lung function and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Kunihiro Matsushita; David Couper; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-10-13       Impact factor: 5.162

8.  Television Watching as Sedentary Behavior and Atrial Fibrillation: The Atherosclerosis Risk in Communities Study.

Authors:  Yasuhiko Kubota; Alvaro Alonso; Amil M Shah; Lin Y Chen; Aaron R Folsom
Journal:  J Phys Act Health       Date:  2018-11-21

9.  β-Thromboglobulin and incident cardiovascular disease risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Alvaro Alonso; Aaron R Folsom
Journal:  Thromb Res       Date:  2017-05-17       Impact factor: 3.944

10.  Incidence of venous thromboembolism and bleeding after pulmonary lobectomy: evaluating the timing for thromboprophylaxis.

Authors:  David Smith; Micaela Raices; Carolina Diego; Drago Julián; Juan Montagne; Agustín Dietrich
Journal:  J Thromb Thrombolysis       Date:  2020-09-14       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.